SKCD in Early Relapsed/Refractory Multiple Myeloma

Recruiting

Plain-English translation of NCT07931391 on ClinicalTrials.gov ↗ · Source last updated November 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(1 site)

China

Beijing Chao-Yang Hospital,Capital Medical University, Beijing, Beijing Municipality

Key details

Phase

Testing effectiveness

Sponsor

Beijing Chao Yang Hospital

Collaborators

BeOne Medicines, Wuhan Hiteck Biological Pharma Co., Ltd.

Enrollment target

~66 participants

Started

October 2026

Primary completion

March 2030

Age range

18 Years and older

Last updated on clinicaltrials.gov in November 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Wen Gao, MD

Beijing Chao Yang Hospital

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov